Case report: Diffuse cutaneous leishmaniasis by Leishmania infantum in a patient undergoing immunosuppressive therapy: risk status in an endemic Mediterranean area. by Alcover Amengual, Maria Magdalena et al.
Am. J. Trop. Med. Hyg., 98(5), 2018, pp. 1313–1316
doi:10.4269/ajtmh.17-0769
Copyright © 2018 by The American Society of Tropical Medicine and Hygiene
Case Report: Diffuse Cutaneous Leishmaniasis by Leishmania infantum in a Patient Undergoing
Immunosuppressive Therapy: Risk Status in an Endemic Mediterranean Area
M. Magdalena Alcover,1 Vicenç Rocamora,2 M. Carmen Guille´n,1 Diana Berenguer,1 Marta Cuadrado,3 Cristina Riera,1
and Roser Fisa1*
1Laboratory of Parasitology, Department of Biology, Health and Environment, Faculty of Pharmacy and Food Science, University of Barcelona,
Barcelona, Spain; 2Department of Dermatology, Hospital de Manacor, Balearic Islands, Spain; 3Department of Pathology, Hospital de Manacor,
Balearic Islands, Spain
Abstract. This case report highlights the risk of severe cutaneous leishmaniasis (CL) by Leishmania infantum in patients
undergoing immunosuppressant therapywhoeither live inanendemicareaor are visiting in the transmissionseason.Thecase
patient, resident in Majorca (Balearic Islands), presented 12 disseminated erythematous skin lesions, 1–6 cm in diameter,
located on the scalp, cheek, umbilical region, and lower extremities 8 years after undergoing anti–tumor necrosis factor (TNF)
therapy. Parasite presence in peripheral blood and high levels of speciﬁc antibodieswere also observed, indicating a possible
risk of CL shifting toward a visceral infection. However, once CL was diagnosed, anti-TNF therapy was discontinued and
liposomal amphotericinBwas administered, resulting in a complete healing of lesions, noLeishmaniaDNAdetection in blood,
and an important serological decrease in antibodies. The lack of data on the supposed epidemiological association between
leishmaniasis and immunosuppressive therapy highlights the importance of implementing surveillance systems in endemic
areas. No obvious relationship was found based on the data provided by the Balearic Islands Epidemiological System, in
contrast with data reported in nearby endemic areas. This indicates that if the suspected association is to be clariﬁed, greater
efforts are needed to report information about concomitant diseases and therapies in leishmaniasis patients.
INTRODUCTION
Although immunosuppressive therapy can be highly effec-
tive for several immune-mediated diseases, tumor necrosis
factor (TNF) inhibitors are associated with an increased risk of
opportunistic infections,1 including histoplasmosis and tuber-
culosis aswell as clinical formsof cutaneous leishmaniasis (CL)
and visceral infection (VL) and even a mucocutaneous form
(ML).2–6 Leishmaniasis, classed among the world’s most
neglected diseases, is a group of parasitic diseases caused by
protozoa of the genus Leishmania. Development of cutaneous,
mucocutaneous, or visceral forms depends on the Leishmania
species involved and the immune response of the host. The
disease caused by Leishmania infantum is endemic in Medi-
terranean countries. In Spain, the two main clinical forms in
humansareCLandVL,with somecasesofMLbeing reported.7
In immunocompetent patients, the normal course of CL by
L. infantum is spontaneous healing, whereas the clinical char-
acteristics in cases of immunosuppression are more severe.8
CASE REPORT
We report the case of a 55-year-old male patient resident
in Majorca in the Balearic Islands, who was diagnosed
with psoriasis and rheumatoid arthritis 27 years ago and de-
veloped multiple disseminated erythematous skin lesions
8 years after undergoing anti-TNF therapy.
In December 2015, when visited in the Dermatology De-
partment of theHospital deManacor,Majorca, the patient had
12 disseminated erythematous cutaneous lesions, seven of
which had a crusty surface with a raised border and produced
a serous exudate when the scab was removed. The dimen-
sions of these lesions ranged from 1 to 6 cm in diameter in all
locations (scalp, cheek, umbilical region, and lower extremi-
ties) (Figure 1). A skin biopsy specimenwas collected from the
lesion located in the upper right knee. A histology analysis by
hematoxylin and eosin staining revealed forms compatible
with Leishmania amastigotes, and an L. infantum strain was
isolated after culture using Novy–MacNeal–Nicolle and
Schneider media, molecularly typed by polymerase chain re-
action (PCR)–restriction fragment length polymorphism.9 A
scab sample was collected from the same lesion onWhatman
ﬁlter paper no. 3 for a real time polymerase chain reaction
(qPCR),10 which gave a positive result for Leishmania, also
identiﬁed molecularly as L. infantum.9 At the same time, pe-
ripheral blood was extracted from the patient for serological
and molecular studies. A serological study by Western blot
(WB)11 identiﬁed the speciﬁc band pattern for Leishmania (14,
16, 24, 28, 30, 46, 65, and 70 kDa). In an in-house enzyme-
linked immunosorbent assay (ELISA),11 high levels of anti-
bodies were observedwith a serological titter of 170U (cut-off
ELISA >20 U). The qPCR of the buffy coat gave a positive
result with a low parasitic level detected (threshold cycle 39),
although the in vitro culture was negative because of its lower
sensitivity. These results may be explained by a low level of
circulating parasites, which would be sufﬁcient to render a
positive PCR but not a positive culture.12 In the clinical ex-
amination and the analytical tests, no parameters suggestive
of visceral involvement were observed, but because of the
extensive cutaneous involvement, a regimen similar to that for
VL affection was initiated. Treatment of diffuse CL began with
intravenous Ambisome® (liposomal amphotericin B) (i.v.): 1–5,
10, 17, 24, 31, and 38 days with treatment, 400 mg daily (×10
days/total dose 40 g). The ﬁrst four doses were administered
to the patient when hospitalized and the remaining six were
given weekly in the Internal Medicine Department without in-
cident. The patient discontinued biological treatment, taking
only corticoids. After 6 months, the lesions had totally dis-
appeared and some presented hyperpigmentation (Figure 1).
In the patient posttreatment follow-up in December 2016,
when anti-TNF treatment had not yet been resumed, no
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Leishmania DNA in blood was detected by qPCR of the buffy
coat, and a serological decrease in the ELISA values and band
intensity and number was observed (Table 1).
DISCUSSION
In cases of human CL, immunosuppressive treatment can
modulate the clinical expression of leishmaniasis, as indicated
in other studies,2 which describe CL cases with more severe
symptoms than in immunocompetent patients. In patients
with a background of rheumatoid arthritis, the risk of serious
infection by Mycobacteria spp., Staphylococcus aureus,
Listeria monocytogenes, Varicella zoster virus, and Leish-
mania spp. appears to be approximately 2-fold higher than in
non–rheumatoid arthritis patients before any biological
therapy.13 Taking into account the existence of this risk,
Marcoval et al.2 recommend that in endemic leishmaniasis
areas, the patient’s immune status against Leishmania be
evaluated before the onset of and during anti-TNF treatment.
The current case, which exempliﬁes the severity of clinical
manifestations of CL, was diagnosed during the course of
anti-TNF treatment in a patient living in an endemic area of
FIGURE 1. Clinical evolution of four of 12 leishmania skin lesions of the patient after 1 year of treatmentwith liposomal amphotericin B (i.v.). (A and
B) Evolution of skin lesion on the scalp. (C andD) Evolution of skin lesion in the cheek. (E andF) Evolution of two skin lesions in the lower extremities.
TABLE 1
Diagnostic techniques and samples studied pre- and posttreatment with Ambisome (liposomal amphotericin B)
Biopsy FPLI Buffy coat Blood serum
Pre-T Pre-T Pre-T Post-T Pre-T Post-T
Culture* Positive – Growth not detected – – –
PCR (Ct) – Positive (Ct 24) Positive (Ct 39) Negative (Ct 45) – –
WB (kDa) – – – – 14, 16, 24, 28, 30, 46, 65, 70 14, 16, 30, 46, 65, 70
ELISA (units) – – – – 170 U 35 U
Ct = threshold cycle; ELISA = enzyme-linked immunosorbent assay; FPLI = ﬁlter paper lesion impression; Post-T = posttreatment; Pre-T = pretreatment; WB = Western blot.
* Three months monitoring.
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L. infantum. After being diagnosed with arthritis and psoriasis
27 years ago, he was initially treated with low doses of corti-
costeroidsandbegananti-TNF therapy in2007, 8 yearsbefore
developingCLsymptoms.As there is no information about the
patient’s immune status before the appearance of the symp-
toms, it is difﬁcult to determine whether the CL is due to
reactivation of a cryptic infection or a new infection.
Although most reports suggest that anti-TNF treatment
favors the onset of atypical lesions in CL patients,2,14 a strong
link has also been established between the development of
leishmaniasis, corticosteroids, and immune status.4,15 Other
studies also indicate that in CL patients with severe lesions
causedbyLeishmania braziliensis, anti-TNF treatment canhelp
thehealingprocessandenhanceulcer cicatrization,16 although
no consensus has been established.17 In the present case, it
is difﬁcult to determine whether the severity of the CL symp-
toms was due to the concomitant disease, the administration
of anti-TNF drugs or cortisone, or a combination of factors.
The presence of multiple lesions due to L. infantum, high
levels of speciﬁc antibodies, and the detection of Leishmania
DNA in peripheral blood all indicate that this type of patient
should be treated with a regimen similar to that for VL. Sub-
sequentmonitoring is also advised to ensure a good prognosis
and complete healing of the disease, avoiding the risk of a shift
toward VL. In the posttreatment follow-up, the lesions had to-
tally disappeared, no Leishmania DNA was detected in blood,
and a signiﬁcant serological decrease in the intensity and
number of bands and ELISA values was observed. The loss of
intermediate bands in theWBagreeswith observations in other
studies that bands of 12–30 kDa are the ﬁrst to disappear
when clinical improvement is observed and the disease is self-
limited.11 The patient was discharged and the reestablishment
of immunosuppressant therapy is being considered.
To clarify the suspected epidemiological association be-
tween leishmaniasis and the use of immunosuppressant ther-
apy, risk assessment was carried out by compiling and
analyzing data provided by the Balearic Islands Epidemiologi-
cal System and from other geographical areas of Spain.
Leishmaniasis is of public health signiﬁcance and a notiﬁable
disease in Spain, but the reported cases of CL between 1989
and 2008 represent only a third of the real incidence, because
many CL patients are treated by dermatologists outside hos-
pitals and go unreported.18 The zones of Spainwith the highest
incidence rate of leishmaniasis are Catalonia, the Balearic Is-
lands,Madrid, and theMediterranean areasofAndalusia, being
between 0.45 and 2.83/100,000 inhabitants for 2009–2014.19
According to the ofﬁcial data for 2005–2015,20 the overall HL
rate in the Balearic Islands in this period was 0.7–3.7 cases per
year/100,000 inhabitants, with a 3:1 ratio of CL and VL cases.
This proportion of CL cases is high compared with those re-
ported in France (1:1), according to a review by Bañuls et al.21
When evaluating the incidence and epidemiological data of
leishmaniasis, the only variables considered signiﬁcant by the
Balearic Islands epidemiological service are pediatric age
groups and human immunodeﬁciency virus patients. In-
formation on other types of immunosuppression, such as
those caused by anti-TNF treatments, is not given a signiﬁ-
cance status. Among the 161 cases of human leishmaniasis
declared in the period between 2010 and 2016 (23.4% VL,
77.6%CL), the involvementof immunosuppressivedisease (not
related to HIV or in children) is unknown in only 10.5% and
linked in 6.8%.
According to our epidemiological review, patients treated with
anti-TNF drugs in Mediterranean endemic areas such as Majorca
do not appear to have a much higher risk of developing leish-
maniasiscomparedwith immunocompetent individuals.However,
in the autonomous community of Valencia, where immunosup-
pressive diseases and immunosuppressive treatment have been
classed as risk factors for leishmaniasis since 2007,22 21.15% of
reported cases of leishmaniasis in 2015 also notify concomitant
immunosuppressive disease and 19.23% treatment with an
immunosuppressant.22 This discrepancy among data from
different geographical areas of Spain suggests a need to raise
awareness about the importance of reporting concomitant
diseases and therapies in leishmaniasis patients. Providing
more comprehensive information in the leishmaniasis notiﬁ-
cation forms and a more systematic reporting of cases would
help to clarify the suspected epidemiological association be-
tween leishmaniasis and immunosuppressant therapy.
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